Applications, hearings, determinations, etc.: Sigma Aldrich Research Biochemicals, Inc.,

[Federal Register: September 25, 2000 (Volume 65, Number 186)]

[Notices]

[Page 57623-57624]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr25se00-87]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated May 12, 2000, and published in the Federal Register on June 2, 2000, (65 FR 35397), Sigma Aldrich Research Biochemicals, Inc., Attn: Richard Milius, 1-3 Strathmore Road, Natick, Massachusetts 01760, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug

Schedule

Cathinone (1235)........................... I Methcathinone (1237)....................... I Aminorex (1585)............................ I Alpha-Ethyltryptamine (7249)............... I Lysergic acid diethylamide (7315).......... I Tetrahydrocannabinols (7370)............... I 4-Bromo-2, 5-dimethoxyam-.................. I phetamine (7391)........................... 4-Bromo-2, 5-dimethoxyphen-................ I ethylamine (7392).......................... 2, 5-Dimethoxyamphetamine (7396)........... I 3, 4-Methylendioxyamphetamine (7400)....... I N-Hydroxy-3, 4-methylenedioxy-............. I amphetamine (7402)......................... 3, 4-Methylenedioxy-N-ethylam-............. I phetamine (7404)........................... 3,4-Methylenedioxymethamphetamine (7405)... I Psilocybin (7437).......................... I 1-[1- (2-Thienyl)cyclo-.................... I hexyl]piperidine (7470).................... Heroin (9200).............................. I Normorphine (9313)......................... I Amphetamine (1100)......................... II Methamphetamine (1105)..................... II Pentobarbital (2270)....................... II Phenylcyclohexylamine (7460)............... II Phencyclidine (7471)....................... II Cocaine (9041)............................. II Codenine (9050)............................ II Diprenorphine (9058)....................... II Benzoylecgonine (9180)..................... II Levomethorphan (9210)...................... II Levorphanol (9220)......................... II Meperidine (9230).......................... II Metazocine (924)........................... II Methadone (9250)........................... II Morphine (9300)............................ II Thebaine (9333)............................ II Levo-alphacetylmethadol (LAAM) (9648)...... II Fentanyl (9801)............................ II

The firm plans to manufacture the listed controlled substances for laboratory reference standards and neurochemicals.

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Sigma Aldrich Research Biochemicals, Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included

[[Page 57624]]

inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

August 18, 2000. John H. King, Deputy Assistant Administrator Office of Diversion Control Drug Enforcement Administration.

[FR Doc. 00-24562Filed9-22-00; 8:45 am]

BILLING CODE 4410-09-M

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT